Development Awards and Deferred Revenue (Details Narrative) - USD ($)
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
9 Months Ended |
12 Months Ended |
Jan. 26, 2018 |
Apr. 20, 2015 |
Apr. 20, 2015 |
May 31, 2019 |
Apr. 30, 2019 |
Mar. 31, 2019 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Jun. 30, 2019 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Dec. 31, 2018 |
Dec. 31, 2017 |
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue recognized |
|
|
|
|
|
|
|
|
|
|
|
$ (6,570,048)
|
|
|
|
| Revenue |
|
|
|
|
|
|
$ 2,589,783
|
|
$ 1,090,878
|
|
|
33,570,048
|
$ 2,894,966
|
|
|
| Additional paid in capital, fair value of warrant issued |
|
|
|
|
|
|
|
|
|
|
|
|
6,215,225
|
|
|
| Cystic Fibrosis Foundation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments for royalty |
|
|
|
$ 2,700,000
|
|
|
|
|
|
|
|
|
|
|
|
| Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront payment, received from related party |
|
|
|
|
|
$ 27,000,000
|
|
|
|
|
|
|
|
|
|
| Consideration receivable on milestone payments |
|
|
|
|
|
$ 173,000,000
|
|
|
|
|
|
|
|
|
|
| Royalty term description |
|
|
|
|
|
The period beginning on the date of the first commercial sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party's insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days' notice
|
|
|
|
|
|
|
|
|
|
| Revenue from related parties, recorded as deferred revenue |
|
|
|
|
|
$ 27,000,000
|
|
|
|
|
|
|
|
|
|
| Revenue recognized |
|
|
|
|
|
|
|
$ 27,000,000
|
|
|
|
|
|
|
|
| Royalty payable |
|
|
|
$ 2,700,000
|
|
|
|
|
|
|
|
|
|
|
|
| Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from investments on achieving milestones |
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
$ 17,500,000
|
|
|
|
|
| Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development award received |
$ 25,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payment percentage |
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment Agreement [Member] | 2018 CFF Award [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
$ 2,589,783
|
|
$ 1,090,878
|
|
|
$ 6,570,048
|
$ 2,894,966
|
|
|
| Investment Agreement [Member] | CFF Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant to purchase of common stock |
|
|
|
|
|
|
1,000,000
|
|
|
|
|
1,000,000
|
|
|
|
| Warrant exercisable price per share |
|
|
|
|
|
|
$ 13.20
|
|
|
|
|
$ 13.20
|
|
|
|
| Warrants expiration term |
|
|
|
|
|
|
Jan. 26, 2025
|
|
|
|
|
Jan. 26, 2025
|
|
|
|
| Investment Agreement [Member] | CFF Warrant [Member] | Immediately Exercisable Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant to purchase of common stock |
|
|
|
|
|
|
500,000
|
|
|
|
|
500,000
|
|
|
|
| Investment Agreement [Member] | CFF Warrant [Member] | Warrants Exercisable On Completion Of Final Milestone [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant to purchase of common stock |
|
|
|
|
|
|
500,000
|
|
|
|
|
500,000
|
|
|
|
| Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 17,500,000
|
|
| Additional paid in capital, fair value of warrant issued |
|
|
|
|
|
|
|
|
|
|
|
$ 6,215,225
|
|
|
|
| Revenue to be recognized |
|
|
|
|
|
|
$ 18,784,775
|
|
|
|
|
$ 18,784,775
|
|
|
|
| Research and development period |
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years 9 months
|
|
| 2015 CFFT Award Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,440,195
|
| Proceeds from investment award |
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cumulative effect of new accounting principle |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payments, description |
|
|
(i) a royalty payment equal to five times the amount the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments following the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale of lenabasum, (ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up to $5 million, due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million, and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses lenabasum in the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change of control transaction, with such payment(s) to be credited against the royalty payments due upon commercialization.
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 CFFT Award Agreement [Member] | First Commercial Sale [Member] | Lenabasum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment due period after the first commercial sale |
|
|
90 days
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 CFFT Award Agreement [Member] | Upon Reaching the Sales Target [Member] | Lenabasum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payment, sales target |
|
500,000,000
|
$ 500,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 CFFT Award Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development award received |
|
5,000,000
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 CFFT Award Agreement [Member] | Maximum [Member] | Upon Commercialization of the Product [Member] | Lenabasum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payable |
|
25,000,000
|
25,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 CFFT Award Agreement [Member] | Maximum [Member] | Upon Reaching the Sales Target [Member] | Lenabasum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payable |
|
5,000,000
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 CFFT Award Agreement [Member] | Maximum [Member] | Upon Transfer, Sale or Licensing [Member] | Lenabasum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payable |
|
$ 15,000,000
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|